The serum pepsinogen levels for risk assessment of gastric neoplasms

Medicine (United States)

Volumn 96, Issue 29, 2017, Pages

  Cho, Jun Hyung ^a   Jeon, Seong Ran ^a   Kim, Hyun Gun ^a   Jin, So Young ^a   Park, Suyeon ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

atrophy; gastric neoplasm; Helicobacter pylori; pepsinogen; risk

Indexed keywords

PEPSINOGEN; PEPSINOGEN II; TUMOR MARKER;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HIGH RISK POPULATION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; AGED; BLOOD; MIDDLE AGED; ODDS RATIO; SOUTH KOREA; STOMACH NEOPLASMS;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PEPSINOGEN A; PEPSINOGEN C; REPUBLIC OF KOREA; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 85026416221     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007603     Document Type: Article

References (50)

1. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9: 279-87.
2. Oh CM, Won YJ, Jung KW, et al. Cancer statistics in Korea: incidence, mortality, survival, and Prevalence in 2013. Cancer Res Treat 2016; 48: 436-50.
3. Kim Y, Jun JK, Choi KS, et al. Overview of the National Cancer Screening Programme and the cancer screening status in Korea. Asian Pac J Cancer Prev 2011; 12: 725-30.
4. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
5. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-Term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-8.
6. Samloff IM. Pepsinogens I and II: purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology 1982; 82: 26-33.
7. Samloff IM, Varis K, Ihamaki T, et al. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology 1982; 83: 204-9.
8. Mukoubayashi C, Yanaoka K, Ohata H, et al. Serum pepsinogen and gastric cancer screening. Intern Med 2007; 46: 261-6.
9. Miki K, Ichinose M, Shimizu A, et al. Serum pepsinogen as a screening test of extensive chronic gastritis. Gastroenterol Jpn 1987; 22: 133-41.
10. Kodoi A, Yoshihara M, Sumii K, et al. Serum pepsinogen in screening for gastric cancer. J Gastroenterol 1995; 30: 452-60.
11. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-40.
12. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 3: 87-97.
13. Lorente S, Doiz O, Trinidad Serrano M, et al. Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells. Gut 2002; 50: 13-8.
14. Miki K, Ichinose M, Kawamura N, et al. The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn J Cancer Res 1989; 80: 111-4.
15. Kitahara F, Kobayashi K, Sato T, et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44: 693-7.
16. Miki K, Morita M, Sasajima M, et al. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003; 98: 735-9.
17. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109: 138-43.
18. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764-8.
19. Choi KS, Suh M. Screening for gastric cancer: the usefulness of endoscopy. Clin Endosc 2014; 47: 490-6.
20. Choi KS, Jun JK, Suh M, et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea. Br J Cancer 2015; 112: 608-12.
21. Shin WG, Kim HU, Song HJ, et al. Surveillance strategy of atrophic gastritis and intestinal metaplasia in a country with a high prevalence of gastric cancer. Dig Dis Sci 2012; 57: 746-52.
22. Choi IJ. Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin Endosc 2014; 47: 497-503.
23. Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631-6.
24. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150-8.
25. el-Zimaity HM, Graham DY, al-Assi MT, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 1996; 27: 35-41.
26. Anagnostopoulos GK, Yao K, Kaye P, et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-Associated gastritis, and gastric atrophy. Endoscopy 2007; 39: 202-7.
27. Inoue T, Uedo N, Ishihara R, et al. Autofluorescence imaging videoendoscopy in the diagnosis of chronic atrophic fundal gastritis. J Gastroenterol 2010; 45: 45-51.
28. Pimentel-Nunes P, Libânio D, Lage J, et al. A multicenter prospective study of the real-Time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. Endoscopy 2016; 48: 723-30.
29. di Mario F, Cavallaro LG. Non-invasive tests in gastric diseases. Dig Liver Dis 2008; 40: 523-30.
30. Kang JM, Kim N, Yoo JY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter 2008; 13: 146-56.
31. Choi HS, Lee SY, Kim JH, et al. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm. J Dig Dis 2014; 15: 293-8.
32. Park CH, Kim EH, Jung da H, et al. The new modified ABCD method for gastric neoplasm screening. Gastric Cancer 2016; 19: 128-35.
33. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A, et al. Serum pepsinogen I, pepsinogen II, and gastric 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 2008; 6: 174-9.
34. Kim EH, Kang H, Park CH, et al. The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis. Dig Liver Dis 2015; 47: 663-8.
35. Mizuno S, Miki I, Ishida T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci 2010; 55: 3132-7.
36. Shimoyama T, Aoki M, Sasaki Y, et al. ABC screening for gastric cancer is not applicable in a Japanese population with high prevalence of atrophic gastritis. Gastric Cancer 2012; 15: 331-4.
37. Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels: the ABC method. Digestion 2016; 93: 13-8.
38. Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systemic review and meta-Analysis. PLoS One 2014; 9: e109783.
39. Charvat H, Sasazuki S, Inoue M, et al. Prediction of the 10-year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II. Int J Cancer 2016; 138: 320-31.
40. Ikeda F, Shikata K, Hata J, et al. Combination of Helicobacter pylori antibody and serum pepsinogen as a good predictive tool of gastric cancer incidence: 20-year prospective data from the Hisayama study. J Epidemiol 2016; 26: 629-36.
41. Inoue K. Suzuki H, Warren R, Marshall B. Stratification of gastric cancer risk by H pylori infection. Helicobacter pylori Springer, Tokyo: 2016; 169-79.
42. Kitamura Y, Yoshihara M, Ito M, et al. Diagnosis of Helicobacter pyloriinduced gastritis by serum pepsinogen levels. J Gastroenterol Hepatol 2015; 30: 1473-7.
43. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-600.
44. Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol 2014; 49: 1-8.
45. Kiyohira K, Yoshihara M, Ito M, et al. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol 2003; 38: 332-8.
46. Yoshida T, Kato J, Inoue I, et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer 2014; 134: 1445-57.
47. Kato M, Nishida T, Tsutsui S, et al. Endoscopic submucosal dissection as a treatment for gastric noninvasive neoplasia: a multicenter study by Osaka University ESD Study Group. J Gastroenterol 2011; 46: 325-31.
48. Carmack SW, Genta RM, Graham DY, et al. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol 2009; 6: 331-41.
49. Goddard AF, Badreldin R, Pritchard DM, et al. British Society of GastroenterologyThe management of gastric polyps. Gut 2010; 59: 1270-6.
50. Liu Y, Uemura N, Xiao SD, et al. Agreement between endoscopic and histological gastric atrophy scores. J Gastroenterol 2005; 40: 123-7.